The U.S. point of care drug of abuse (DOA) testing market size was estimated at USD 370.55 million in 2024 and is projected to grow at a CAGR of 9.3% from 2025 to 2033. The market is driven by an increasing need for rapid and on-site drug testing across multiple settings. Point-of-care DOA tests, which include urine, saliva, and occasionally blood-based panels, are widely used in workplaces, emergency departments, law enforcement, rehabilitation centers, and schools. These tests offer immediate results, helping healthcare professionals and institutions make faster decisions related to patient care, compliance, and risk mitigation. Their portability and ease of use are further increasing their adoption among non-laboratory professionals, contributing to market penetration.
One of the primary market drivers is the escalating incidence of drug abuse in the U.S., particularly related to opioids, cannabis, cocaine, and amphetamines. According to the National Center for Drug Abuse Statistics, over 20 million Americans aged 12 and older had a substance use disorder in 2023. This rising trend has heightened the demand for efficient drug screening tools, particularly in emergency and occupational health settings. Additionally, increased funding from federal agencies such as SAMHSA (Substance Abuse and Mental Health Services Administration) and state-level opioid response programs has bolstered the adoption of rapid testing tools.
Mandates for pre-employment, random, and post-incident drug testing in safety-sensitive industries such as transportation, construction, and healthcare are significantly contributing to market growth. The U.S. Department of Transportation (DOT) and other regulatory bodies have stringent requirements that compel employers to implement DOA screening protocols. POC testing is especially valued in these settings for its ability to quickly identify intoxication or recent drug use, helping mitigate legal liability and ensure workforce safety.
This product will be delivered within 1-3 business days.
One of the primary market drivers is the escalating incidence of drug abuse in the U.S., particularly related to opioids, cannabis, cocaine, and amphetamines. According to the National Center for Drug Abuse Statistics, over 20 million Americans aged 12 and older had a substance use disorder in 2023. This rising trend has heightened the demand for efficient drug screening tools, particularly in emergency and occupational health settings. Additionally, increased funding from federal agencies such as SAMHSA (Substance Abuse and Mental Health Services Administration) and state-level opioid response programs has bolstered the adoption of rapid testing tools.
Mandates for pre-employment, random, and post-incident drug testing in safety-sensitive industries such as transportation, construction, and healthcare are significantly contributing to market growth. The U.S. Department of Transportation (DOT) and other regulatory bodies have stringent requirements that compel employers to implement DOA screening protocols. POC testing is especially valued in these settings for its ability to quickly identify intoxication or recent drug use, helping mitigate legal liability and ensure workforce safety.
U.S. Point of Care Drug of Abuse Testing Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. point of care drug of abuse (DOA) testing market report based on product, sample type, technology, and end-use:Product Outlook (Revenue, USD Million, 2021 - 2033)
- Immunoassay Test Strips and Cassettes
- Oral Fluid Testing Kits
- Breath Analyzers
- Urine Collection Cups
- Digital/Portable Analyzers
Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
- Urine
- Saliva (Oral Fluid)
- Breath
- Blood
- Sweat/Hair
Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Lateral Flow Assay (LFA)
- Chromatographic Immunoassays
- Enzyme-linked Immunosorbent Assay (ELISA)
- Mass Spectrometry (Portable or Hybrid POC Units)
End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & Emergency Departments
- Workplace & Occupational Health Center
- Home Care & Remote Users
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Point of Care Drug of Abuse (DOA) Testing Market Variables, Trends, & Scope
Chapter 4. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Estimates & Trend Analysis
Chapter 6. U.S. Point of Care Drug of Abuse (DOA) Testing Market: Technology Estimates & Trend Analysis
Chapter 7. U.S. Point of Care Drug of Abuse (DOA) Testing Market: End Use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Abbott
- Quest Diagnostics
- Thermo Fisher Scientific
- OraSure Technologies
- Siemens Healthineers
- F. Hoffmann-La Roche Ltd.
- Drägerwerk AG & Co. KGaA
- Premier Biotech
- American Screening Corporation, Inc.
- Innovacon (acquired by Alere, now Abbott)
- MP Biomedicals
- Aegis Sciences Corporation
